Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB has initiated EXXELERATE study to compare the relative efficacy of Cimzia (certolizumab pegol) and Humira (adalimumab) in the treatment of moderate to severe rheumatoid arthritis.
Subscribe to our email newsletter
The primary objectives of the multi-centre, single-blind study are to compare the relative efficacy of the two anti-TNF therapies during short- and long-term treatment (12 and 104 weeks respectively).
The parallel-group study will randomize patients to either rcertolizumab pegol plus MTX or adalimumab plus MTX.
The headline results from the study are expected in 2016.
UCB chief medical officer and executive vice president Iris Loew-Friedrich said EXXELERATE should provide additional evidence to support early, informed management decisions for people living with this chronic, progressive disease.